Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • Duration of virologic suppression is an important factor to consider before modifying an antiretroviral regimen, particularly if there is a need to use regimens of lower potency or lower genetic barrier to resistance
  • Available data from ritonavir-boosted PI monotherapy trials demonstrate more favorable virologic outcomes when this approach is used in patients who have experienced virologic suppression for at least 6 months[Delfraissy 2008; Cameron 2008; Arribas 2005; Pulido 2008a]
    • Very low baseline HIV-1 RNA level is an additional factor for predicting treatment success
    • Switch to a Less Potent Regimen
      Effect of Adherence After Durable Virologic Suppression

      Action required

      Keywords: Switch Strategies

      ©2020 Clinical Care Options, LLC. All Rights Reserved.

      The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.